Which interventricular septal diameter measurement—diastolic (IVS(d)) or systolic (IVS(s))—determines the severity of hypertrophic cardiomyopathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Interventricular Septal Diameter Measurement in HCM Severity Assessment

The diastolic interventricular septal diameter (IVS(d)) determines the severity of hypertrophic cardiomyopathy, not the systolic measurement. This is the standard measurement used for diagnosis, risk stratification, and clinical decision-making in HCM.

Measurement Timing and Rationale

Maximum diastolic wall thickness is the established standard for assessing HCM severity because the septum is thickest and most clearly defined at end-diastole, providing the most accurate and reproducible measurement 1, 2. The American College of Cardiology/American Heart Association guidelines specifically recommend measuring "maximum diastolic wall thickness" using 2D short-axis views in all LV segments from base to apex, with measurements obtained at end-diastole 1.

Why Diastolic Measurement is Critical

  • Diagnostic threshold: The conventional diagnostic criterion for HCM in adults is a maximal wall thickness ≥15 mm measured at end-diastole 1
  • Risk stratification: Maximum diastolic wall thickness ≥30 mm is independently associated with sudden cardiac death and directly influences ICD decision-making 1
  • Linear mortality correlation: There is a relatively linear association between maximal diastolic wall thickness and sudden death risk, with highest risk in patients with wall thickness ≥30 mm 3
  • Prognostic significance: Severe septal hypertrophy (IVSd ≥25 mm) carries a 5-fold increased risk of all-cause mortality compared to IVSd <20 mm 4

Clinical Application

The diastolic measurement serves multiple critical functions:

  • Surgical planning: Baseline IVSd determines the extent of myectomy required and predicts post-procedural outcomes 5, 4
  • Intervention thresholds: Patients with extreme IVSd (≥30 mm) have higher incidence of adverse cardiovascular events and worse surgical outcomes, with 5-year survival significantly lower than those with IVSd <30 mm 5
  • Family screening: IVSd measurement is used for periodic screening of first-degree relatives and genotype-positive, phenotype-negative individuals 6

Common Pitfall to Avoid

Do not confuse septal thickness measurement timing with LVOT gradient measurement timing. While maximal wall thickness must be measured during diastole, LVOT gradients are measured during systole using peak instantaneous velocity 1. The ACC/AHA guidelines emphasize avoiding this confusion, as measurements must be obtained at the correct cardiac phase: wall thickness during diastole and LVOT gradients during systole 1.

Measurement Protocol

  • Use 2D short-axis views to assess all LV segments from base to apex 1, 6
  • Measure at end-diastole when the septum is maximally thickened 1
  • Document as "maximum diastolic wall thickness" or "IVSd" to avoid misinterpretation 1
  • Consider contrast-enhanced echocardiography if images are suboptimal 6

Prognostic Implications by Thickness Category

Research demonstrates clear mortality stratification based on diastolic septal thickness:

  • IVSd <20 mm: Baseline risk category 4
  • IVSd 20-24 mm: Similar survival to baseline (HR 1.4) 4
  • IVSd ≥25 mm: 5-fold increased mortality risk (HR 5.0) 4
  • IVSd ≥30 mm: Highest risk with significantly reduced 5-year survival (85.7% vs 98.9% for IVSd <30 mm) 5

Baseline IVSd is inversely associated with survival, with each 1 mm increment carrying a hazard ratio of 1.13 for mortality 4.

References

Guideline

Obstructive Hypertrophic Cardiomyopathy Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Left Ventricular Hypertrophy Detection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Role of 2D Echocardiography in Hypertrophic Obstructive Cardiomyopathy (HOCM)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.